PRL and polycystic ovary syndrome: This finding may suggest that dopaminergic agents are less effective in decreasing prolactin production in women with PCOS than in other groups of hyperprolactinemic patients, and that baseline tuberoinfundibular dopaminergic transmission may partially determine the impact of different drugs on lactotrope secretory function.